

CODE/NAME & ADDRESS: C000138376 :41 Years ACCESSION NO: 0062XA000193 AGE/SEX Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID:

DRAWN

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results Biological Reference Interval Units <u>Final</u>

ABHA NO

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

XRAY-CHEST

BOTH THE LUNG FIELDS ARE CLEAR

BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR

BOTH THE HILA ARE NORMAL >> >>

CARDIAC AND AORTIC SHADOWS APPEAR NORMAL **»**» BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL >> >>

VISUALIZED BONY THORAX IS NORMAL **»**»

NORMAL IMPRESSION

ECG

WITHIN NORMAL LIMITS **ECG**

MEDICAL HISTORY

RELEVANT PRESENT HISTORY HIGH BLOOD PRESSURE- 2 YRS, THYROID DISEASE - 9 YRS

NOT SIGNIFICANT RELEVANT PAST HISTORY

MARRIED, 1 CHILDM NON VEG, ALCOHOL-OCCASIONALLY. RELEVANT PERSONAL HISTORY

MENSTRUAL HISTORY (FOR FEMALES) NOT SIGNIFICANT

LMP (FOR FEMALES) 05/12/2023 P1A3L1 LSCS OBSTETRIC HISTORY (FOR FEMALES)

LCB (FOR FEMALES) **13 YRS**

RELEVANT FAMILY HISTORY FATHER- HIGH BLOOD PRESSURE, DIABETES

OCCUPATIONAL HISTORY **BANKING**

HISTORY OF MEDICATIONS THYROXINE - 100 MCG OD

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS mts 1.52 WEIGHT IN KGS. 52.75 Kgs

K. I. Prejipati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 1 Of 24

View Report

PERFORMED AT:





CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 04/01/2024 08:57:22

DELHI ABHA NO REPORTED :05/01/2024 14:22:13 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

23 **BMI** BMI & Weight Status as follows/sqmts

> Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE **NORMAL HEALTHY**

GENERAL APPEARANCE / NUTRITIONAL

STATUS

AVERAGE BUILT / SKELETAL FRAMEWORK NORMAL FACIAL APPEARANCE SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB **NORMAL NECK** NORMAL

NOT ENLARGED OR TENDER NECK LYMPHATICS / SALIVARY GLANDS

NOT ENLARGED THYROID GLAND

CAROTID PULSATION **NORMAL** BREAST (FOR FEMALES) NORMAL NORMAL TEMPERATURE

89/MINUTE REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID **PULSE**

BRUIT

RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

mm/Hg ΒP 140/98 MM HG

(SITTING)

PERICARDIUM NORMAL APEX BEAT **NORMAL**

HEART SOUNDS S1, S2 HEARD NORMALLY

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 2 Of 24

View Report







CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results Biological Reference Interval Units <u>Final</u>

ABSENT **MURMURS**

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST **NORMAL** MOVEMENTS OF CHEST **SYMMETRICAL** BREATH SOUNDS INTENSITY **NORMAL**

VESICULAR (NORMAL) **BREATH SOUNDS QUALITY**

ADDED SOUNDS **ABSENT**

PER ABDOMEN

NORMAL APPEARANCE ABSENT VENOUS PROMINENCE

NOT PALPABLE LIVER SPLEEN NOT PALPABLE

ABSENT HERNIA NIL ANY OTHER COMMENTS

CENTRAL NERVOUS SYSTEM

NORMAL HIGHER FUNCTIONS CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM **NORMAL** MOTOR SYSTEM **NORMAL REFLEXES NORMAL**

MUSCULOSKELETAL SYSTEM

NORMAL SPINE

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 3 Of 24

View Report



Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini



CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: DELHI

ABHA NO **NEW DELHI 110030** 8800465156

DRAWN

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

NORMAL JOINTS

BASIC EYE EXAMINATION

NORMAL CONJUNCTIVA **NORMAL EYELIDS** EYE MOVEMENTS **NORMAL NORMAL CORNEA** DISTANT VISION RIGHT EYE WITHOUT 6/6 **GLASSES** DISTANT VISION LEFT EYE WITHOUT 6/6 **GLASSES** NEAR VISION RIGHT EYE WITHOUT GLASSES N/6 NEAR VISION LEFT EYE WITHOUT GLASSES N/6 **COLOUR VISION NORMAL**

BASIC ENT EXAMINATION

NORMAL EXTERNAL EAR CANAL TYMPANIC MEMBRANE NORMAL

NO ABNORMALITY DETECTED **NOSE**

NORMAL SINUSES NORMAL **THROAT**

NOT ENLARGED TONSILS

BASIC DENTAL EXAMINATION

NORMAL TEETH **GUMS HEALTHY** ANY OTHER COMMENTS NIL

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 4 Of 24

View Report

PERFORMED AT:





CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 04/01/2024 08:57:22

DELHI ABHA NO REPORTED :05/01/2024 14:22:13 **NEW DELHI 110030** 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u>

SUMMARY

NOT SIGNIFICANT RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

WITHIN NORMAL LIMITS RELEVANT LAB INVESTIGATIONS

NO ABNORMALITIES DETECTED RELEVANT NON PATHOLOGY DIAGNOSTICS

REMARKS / RECOMMENDATIONS CEASE ALCOHOL INTAKE NEPHROLOGIST, GYNAECOLOGIST

CONSULTATION MONITOR BP

FITNESS STATUS

FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS) FITNESS STATUS

K. I. Prejupati

Dr. Kamlesh I Prajapati **Consultant Pathologist**





Page 5 Of 24

View Report



Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini

New Delhi, 110085 New Delhi, India Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956





Units

RECEIVED: 04/01/2024 08:57:22

REPORTED :05/01/2024 14:22:13

REF. DOCTOR: SELF PATIENT NAME: UNIKA SACHDEVA

CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: **DELHI**

ABHA NO **NEW DELHI 110030**

8800465156

Results

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ULTRASOUND ABDOMEN

Test Report Status

ULTRASOUND ABDOMEN

ULTRASOUND WHOLE ABDOMEN

Final

Liver is normal in size, outline & normal echotexture. No obvious focal parenchymal lesion/biliary dilatation is seen. Hepatic veins and portal venous radicals are normal.

Gall bladder is not seen (postop).

Pancreas

Pancreas is normal in size, outline and echotexture. No evidence of any focal lesion or calcification is seen.

Pancreatic duct is not dilated.

Spleen

Spleen is normal in size, outline and echotexture .No focal lesion/ calcification is seen.

Both kidneys are normal in size, outline and echotexture. Corticomedullary differentiation is well maintained. Parenchymal thickness is normal. Few small calculi are seen in left kidney, measuring upto 3-4mm. One-two **concretions are seen in right kidney.** No hydronephrosis is seen.

No significant retroperitoneal lymphadenopathy/ascites is seen.

Urinary Bladder

Urinary bladder is adequately distended with normal outline. No mass lesion, calculus or diverticulum is noted in the urinary bladder. Urinary bladder wall thickness is normal.

Uterus

Uterus is anteverted with normal in size outline and shows heterogenous echotexture. An intramuralsubserosal fibroid of size ~37x30mm is noted along anterior wall in lower body region. About two-three seedling fibroids are also seen. Adv-TVS for better evaluation.

Endometrial thickness is 8mm.

No obvious adnexal pathology is seen.

POD is clear.

Correlate clinically

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**

Page 6 Of 24











REF. DOCTOR: SELF PATIENT NAME: UNIKA SACHDEVA

CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID

: UNIKF17108262

CLIENT PATIENT ID: ABHA NO

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results Units **Final**

TMT OR ECHO **CLINICAL PROFILE**

ECHO-IMPRESSION:-

NORMAL BIVENTRICULAR FUNCTION WITH LVEF=60%

Interpretation(s)

MEDICAL

HISTORY-* THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history as well as the comprehensiveness of the diagnostic panel which has been requested for .These are then further correlated with details of the job under consideration to eventually fit the right man to the right job.

Basis the above, Agilus diagnostic classifies a candidate's Fitness Status into one of the following categories:

- Fit (As per requested panel of tests) AGILUS Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for.
- Fit (with medical advice) (As per requested panel of tests) This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician so consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job.
- Fitness on Hold (Temporary Unfit) (As per requested panel of tests) Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly
- elevated blood sugars, etc.
 Unfit (As per requested panel of tests) An unfit report by Agilus diagnostic Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs.

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**

Page 7 Of 24





View Report

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini

8800465156





PATIENT NAME: UNIKA SACHDEVA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262 F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI **NEW DELHI 110030**

CLIENT PATIENT ID: RECEIVED : 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13 ABHA NO

DRAWN

Biological Reference Interval Test Report Status Results Units <u>Final</u>

| F- | IAEMATOLOGY - CE | SC . | |
|---|------------------|-------------|---------|
| MEDI WHEEL FULL BODY HEALTH CHECK UP A | BOVE 40 MALE | | |
| BLOOD COUNTS,EDTA WHOLE BLOOD | | | |
| HEMOGLOBIN (HB) METHOD: CYANMETHEMOGLOBIN METHOD | 12.9 | 12.0 - 15.0 | g/dL |
| RED BLOOD CELL (RBC) COUNT METHOD: IMPEDANCE | 4.65 | 3.8 - 4.8 | mil/μL |
| WHITE BLOOD CELL (WBC) COUNT METHOD: IMPEDANCE | 5.65 | 4.0 - 10.0 | thou/μL |
| PLATELET COUNT METHOD: IMPEDANCE | 293 | 150 - 410 | thou/µL |
| RBC AND PLATELET INDICES | | | |
| HEMATOCRIT (PCV) METHOD: CALCULATED | 40.5 | 36 - 46 | % |
| MEAN CORPUSCULAR VOLUME (MCV) METHOD: CELL COUNTER | 87.2 | 83 - 101 | fL |
| MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER | 27.7 | 27.0 - 32.0 | pg |
| MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER | 31.7 | 31.5 - 34.5 | g/dL |
| RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED | 14.2 High | 11.6 - 14.0 | % |
| MENTZER INDEX METHOD: CALCULATED PARAMETER | 18.8 | | |
| MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER | 11.2 High | 6.8 - 10.9 | fL |
| WBC DIFFERENTIAL COUNT | | | |
| NEUTROPHILS METHOD: IMPEDANCE / MICROSCOPY | 60 | 40 - 80 | % |
| LYMPHOCYTES METHOD: IMPEDANCE / MICROSCOPY | 32 | 20 - 40 | % |

K. I. Prejipati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 8 Of 24

View Report



Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini







PATIENT NAME: UNIKA SACHDEVA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138376 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0062XA000193

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID: ABHA NO

AGE/SEX :41 Years

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

| Test Report Status <u>Final</u> | Results | Biological Reference | Interval Units |
|-----------------------------------|---------|----------------------|----------------|
| | | | |
| MONOCYTES | 6 | 2 - 10 | % |
| METHOD: IMPEDANCE / MICROSCOPY | | | |
| EOSINOPHILS | 2 | 1 - 6 | % |
| METHOD: IMPEDANCE / MICROSCOPY | | | |
| BASOPHILS | 00 | 0 - 2 | % |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| ABSOLUTE NEUTROPHIL COUNT | 3.39 | 2.0 - 7.0 | thou/µL |
| METHOD: CALCULATED PARAMETER | | | |
| ABSOLUTE LYMPHOCYTE COUNT | 1.81 | 1 - 3 | thou/µL |
| METHOD: CALCULATED PARAMETER | | | |
| ABSOLUTE MONOCYTE COUNT | 0.34 | 0.20 - 1.00 | thou/µL |
| METHOD: CALCULATED PARAMETER | | | |
| ABSOLUTE EOSINOPHIL COUNT | 0.11 | 0.02 - 0.50 | thou/µL |
| METHOD: CALCULATED PARAMETER | | | |
| ABSOLUTE BASOPHIL COUNT | 0 Low | 0.02 - 0.10 | thou/µL |
| METHOD: CALCULATED PARAMETER | | | |
| NEUTROPHIL LYMPHOCYTE RATIO (NLR) | 1.9 | | |
| METHOD: CALCULATED PARAMETER | | | |
| | | | |

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

This ratio element is a calculated parameter and out of NABL scope.

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 9 Of 24

View Report



Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini







REF. DOCTOR: SELF PATIENT NAME: UNIKA SACHDEVA

CODE/NAME & ADDRESS: C000138376 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0062XA000193

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

:41 Years

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Biological Reference Interval **Final** Results Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R 05 0 - 20

METHOD: WESTERGREN METHOD

mm at 1 hr

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

Non-diabetic Adult < 5.7 HBA1C 5.3 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0

(ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) mg/dL 105.4 < 116.0

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an ondition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Earloger infection, agring. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 10 Of 24

View Report



Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini







Units

REF. DOCTOR: SELF PATIENT NAME: UNIKA SACHDEVA

CODE/NAME & ADDRESS: C000138376 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

: UNIKF17108262

ACCESSION NO: 0062XA000193 AGE/SEX :41 Years

DRAWN

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results **Biological Reference Interval** <u>Final</u>

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

 GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

PATIENT ID

ABHA NO

CLIENT PATIENT ID:

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

- **HbA1c Estimation can get affected due to :**1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 11 Of 24

View Report

PERFORMED AT:

New Delhi, 110085





CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: DELHI

ABHA NO **NEW DELHI 110030** 8800465156

DRAWN

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results Biological Reference Interval <u>Final</u> Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE B **ABO GROUP**

METHOD: TUBE AGGLUTINATION

RH TYPE **POSITIVE**

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 12 Of 24

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini







CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

:41 Years AGE/SEX Female

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CLIENT PATIENT ID:

ABHA NO

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 100 Normal < 100 ma/dL

Impaired fasting glucose:100 to

Diabetes mellitus: > = 126 (on

more than 1 occassion) (ADA guidelines 2021)

METHOD: HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) SAMPLE NOT mg/dL

RECEIVED

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL < 200 Desirable mg/dL 182

200 - 239 Borderline High

>/= 240 High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE TRIGLYCERIDES 56 < 150 Normal mg/dL

150 - 199 Borderline High

200 - 499 High >/=500 Very High

METHOD: ENZYMATIC, END POINT

METHOD: DIRECT MEASURE POLYMER-POLYANION

HDL CHOLESTEROL 65 High < 40 Low mg/dL

>/=60 High

CHOLESTEROL LDL 106 High < 100 Optimal mg/dL

100 - 129

Near optimal/ above optimal

130 - 159 Borderline High 160 - 189 High >/= 190 Very High

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**

Page 13 Of 24







Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini





CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 04/01/2024 08:57:22

DELHI ABHA NO REPORTED :05/01/2024 14:22:13 **NEW DELHI 110030** 8800465156

| | i | i |
|---------------------------------|---------|--|
| Test Report Status <u>Final</u> | Results | Biological Reference Interval Units |
| | | |
| NON HDL CHOLESTEROL | 117 | Desirable-Less than 130 mg/dL Above Desirable-130-159 |
| | | Borderline High-160-189 |
| | | High-190-219 |
| | | Very High- >or =220 |
| METHOD: CALCULATED | | , 3 |
| VERY LOW DENSITY LIPOPROTEIN | 11.2 | mg/dL |
| CHOL/HDL RATIO | 2.8 Low | 3.3 - 4.4: Low Risk |
| | | 4.5 - 7.0: Average Risk |
| | | 7.1 - 11.0: Moderate Risk |
| | | >11.0: High Risk |
| LDL/HDL RATIO | 1.6 | 0.5 - 3.0 Desirable/Low Risk |
| | | 3.1 - 6.0 Borderline/Moderate |
| | | Risk |
| | | >6.0 High Risk |

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

| Risk Category | | | | |
|------------------------|---|---|--|--|
| Extreme risk group | A.CAD with > 1 feature of high risk group | | | |
| | B. CAD with > 1 feature of Very high risk g | group or recurrent ACS (within 1 year) despite LDL-C < or = | | |
| | 50 mg/dl or polyvascular disease | | | |
| Very High Risk | 1. Established ASCVD 2. Diabetes with 2 r | najor risk factors or evidence of end organ damage 3. | | |
| | Familial Homozygous Hypercholesterolemia | a | | |
| High Risk | 1. Three major ASCVD risk factors. 2. Dia | betes with 1 major risk factor or no evidence of end organ | | |
| | damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary | | | |
| | Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque | | | |
| Moderate Risk | 2 major ASCVD risk factors | | | |
| Low Risk | 0-1 major ASCVD risk factors | | | |
| Major ASCVD (Ath | erosclerotic cardiovascular disease) Risk Fa | ctors | | |
| • | | 3. Current Cigarette smoking or tobacco use | | |
| 2. Family history of p | oremature ASCVD | 4. High blood pressure | | |
| 5. Low HDL | 5. Low HDL | | | |
| T | 1 (() 1 () () () 1 1 1 1 1 1 1 () | 11 141, 2020 | | |

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

| Risk Group | Treatment Goals | | Consider Drug Therapy | |
|------------|-----------------|-----------------|-----------------------|-----------------|
| | LDL-C (mg/dl) | Non-HDL (mg/dl) | LDL-C (mg/dl) | Non-HDL (mg/dl) |

K. I. Prejipati

Dr. Kamlesh I Prajapati **Consultant Pathologist**





Page 14 Of 24

View Report

PERFORMED AT:







PATIENT NAME: UNIKA SACHDEVA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : UNIKF17108262

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 04/01/2024 08:57:22 DELHI

ABHA NO REPORTED :05/01/2024 14:22:13 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

| Extreme Risk Group Category A | <50 (Optional goal | < 80 (Optional goal | >OR = 50 | >OR = 80 |
|-------------------------------|---------------------------|---------------------|-----------|----------|
| | $\langle OR = 30 \rangle$ | <OR = 60) | | |
| Extreme Risk Group Category B | <OR = 30 | <OR = 60 | > 30 | >60 |
| Very High Risk | <50 | <80 | >OR= 50 | >OR= 80 |
| High Risk | <70 | <100 | >OR= 70 | >OR= 100 |
| Moderate Risk | <100 | <130 | >OR= 100 | >OR= 130 |
| Low Risk | <100 | <130 | >OR= 130* | >OR= 160 |

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

| BILIRUBIN, TOTAL | 0.40 | Upto 1.2 | mg/dL |
|---|------|-------------|-------|
| METHOD: DIAZONIUM ION, BLANKED (ROCHE) BILIRUBIN, DIRECT METHOD: DIAZONIUM ION, BLANKED (ROCHE) | 0.14 | Upto 0.2 | mg/dL |
| BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER | 0.26 | 0.00 - 0.90 | mg/dL |
| TOTAL PROTEIN | 7.6 | 6.4 - 8.3 | g/dL |
| ALBUMIN | 4.5 | 3.97 - 4.94 | g/dL |
| METHOD: BROMOCRESOL PURPLE | | | |
| GLOBULIN | 3.1 | 2.0 - 4.0 | g/dL |
| METHOD: CALCULATED PARAMETER | | | |
| ALBUMIN/GLOBULIN RATIO | 1.5 | 1.0 - 2.0 | RATIO |
| METHOD: CALCULATED PARAMETER | | | |
| ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: IFCC WITH PYRIDOXAL 5 PHOSPHATE | 19 | 0 - 32 | U/L |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV WITH P5P-IFCC | 14 | 0 - 33 | U/L |
| | 0.1 | 25 104 | 11/1 |
| ALKALINE PHOSPHATASE METHOD: PNPP, AMP BUFFER-IFCC | 81 | 35 - 104 | U/L |
| GAMMA GLUTAMYL TRANSFERASE (GGT) | 18 | 5 - 36 | U/L |
| METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE-IFCC | 10 | 3 30 | -, - |
| LACTATE DEHYDROGENASE | 171 | 135 - 214 | U/L |
| METHOD : L TO P, IFCC | | | |

BLOOD UREA NITROGEN (BUN), SERUM

mg/dL **BLOOD UREA NITROGEN** 13 6 - 20

METHOD: UREASE - UV

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**





Page 15 Of 24

View Report

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini



^{*}After an adequate non-pharmacological intervention for at least 3 months.





PATIENT NAME: UNIKA SACHDEVA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0062XA000193

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID: ABHA NO : AGE/SEX : DRAWN :

RECEIVED : 04/01/2024 08:57:22

:41 Years

REPORTED :05/01/2024 14:22:13

| Test Report Status | Final | Results | Biological Reference Interval Units |
|-----------------------|----------|----------|--------------------------------------|
| 1 cot itcpoi t otatas | <u> </u> | itcourto | Diological Reference Interval Office |

CREATININE, SERUM

CREATININE 0.62 0.5 - 0.9 mg/dL

METHOD: ALKALINE PICRATE

BUN/CREAT RATIO

BUN/CREAT RATIO **20.97 High** 5.00 - 15.00

URIC ACID, SERUM

URIC ACID 4.4 2.4 - 5.7 mg/dL

TOTAL PROTEIN, SERUM

METHOD: URICASE, COLORIMETRIC

TOTAL PROTEIN 7.6 6.4 - 8.3 g/dL

METHOD : BIURET

ALBUMIN, SERUM

ALBUMIN 4.5 3.97 - 4.94 g/dL

METHOD: BROMOCRESOL PURPLE (BCP) DYE-BINDING

GLOBULIN

GLOBULIN 3.1 2.0 - 4.0 g/dL

METHOD: CALCULATED PARAMETER

ELECTROLYTES (NA/K/CL), SERUM

K.I. Prejapati

Dr. Kamlesh I Prajapati Consultant Pathologist Page 16 Of 24





View Details

View Repor



Agilus Diagnostics Ltd. Plot No.160,Pocket D-11 Sector 8, Rohini





CODE/NAME & ADDRESS : C000138376 ACCESSION NO : **0062XA000193** AGE/SEX : 41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156 ATIENT ID : UNIKF17108262 DRAWN :

CLIENT PATIENT ID: RECEIVED : 04/01/2024 08:57:22
ABHA NO : REPORTED : 05/01/2024 14:22:13

| | i | i | |
|---------------------------------|----------|----------------------|----------------|
| Test Report Status <u>Final</u> | Results | Biological Reference | Interval Units |
| | | | |
| SODIUM, SERUM | 145 | 136 - 145 | mmol/L |
| METHOD: ISE INDIRECT | | | |
| POTASSIUM, SERUM | 3.88 | 3.3 - 5.1 | mmol/L |
| METHOD : ISE DIRECT | | | |
| CHLORIDE, SERUM | 107 High | 98 - 106 | mmol/L |
| METHOD: ISE INDIRECT | | | |

Interpretation(s)

| Sodium | Potassium | Chloride |
|---------------------------------------|--|--|
| Decreased in:CCF, cirrhosis, | Decreased in: Low potassium | Decreased in: Vomiting, diarrhea, |
| vomiting, diarrhea, excessive | intake,prolonged vomiting or diarrhea, | renal failure combined with salt |
| sweating, salt-losing | RTA types I and II, | deprivation, over-treatment with |
| nephropathy, adrenal insufficiency, | hyperaldosteronism, Cushing's | diuretics, chronic respiratory acidosis, |
| nephrotic syndrome, water | syndrome,osmotic diuresis (e.g., | diabetic ketoacidosis, excessive |
| intoxication, SIADH. Drugs: | hyperglycemia),alkalosis, familial | sweating, SIADH, salt-losing |
| thiazides, diuretics, ACE inhibitors, | periodic paralysis,trauma | nephropathy, porphyria, expansion of |
| chlorpropamide,carbamazepine,anti | (transient).Drugs: Adrenergic agents, | extracellular fluid volume, |
| depressants (SSRI), antipsychotics. | diuretics. | adrenalinsufficiency, |
| | | hyperaldosteronism, metabolic |
| | | alkalosis. Drugs: chronic |
| | | laxative,corticosteroids, diuretics. |
| Increased in: Dehydration | Increased in: Massive hemolysis, | Increased in: Renal failure, nephrotic |
| (excessivesweating, severe | severe tissue damage, rhabdomyolysis, | syndrome, RTA,dehydration, |
| vomiting or diarrhea),diabetes | acidosis, dehydration,renal failure, | overtreatment with |
| mellitus, diabetesinsipidus, | Addison's disease, RTA type IV, | saline,hyperparathyroidism, diabetes |
| hyperaldosteronism, inadequate | hyperkalemic familial periodic | insipidus, metabolic acidosis from |
| water intake. Drugs: steroids, | paralysis. Drugs: potassium salts, | diarrhea (Loss of HCO3-), respiratory |
| licorice,oral contraceptives. | potassium- sparing diuretics,NSAIDs, | alkalosis,hyperadrenocorticism. |
| | beta-blockers, ACE inhibitors, high- | Drugs: acetazolamide, and rogens, |
| | dose trimethoprim-sulfamethoxazole. | hydrochlorothiazide, salicylates. |
| Interferences: Severe lipemia or | Interferences: Hemolysis of sample, | Interferences:Test is helpful in |
| hyperproteinemi, if sodium analysis | delayed separation of serum, | assessing normal and increased anion |
| involves a dilution step can cause | prolonged fist clenching during blood | gap metabolic acidosis and in |
| spurious results. The serum sodium | drawing, and prolonged tourniquet | distinguishing hypercalcemia due to |
| falls about 1.6 mEq/L for each 100 | placement. Very high WBC/PLT counts | hyperparathyroidism (high serum |
| mg/dL increase in blood glucose. | may cause spurious. Plasma potassium | chloride) from that due to malignancy |
| | levels are normal. | (Normal serum chloride) |

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas.tolbutamide.and other oral hypoglycemic agents.

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

K.I. Prejipati

Dr. Kamlesh I Prajapati Consultant Pathologist





Page 17 Of 24

View Details

View Report

PERFORMED AT:







REF. DOCTOR: SELF PATIENT NAME: UNIKA SACHDEVA

CODE/NAME & ADDRESS: C000138376 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0062XA000193

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID: ABHA NO

DRAWN

AGE/SEX

:41 Years

RECEIVED: 04/01/2024 08:57:22 REPORTED: 05/01/2024 14:22:13

Test Report Status Results **Biological Reference Interval Final** Units

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. **AST** is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured

clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease,high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein,is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and

globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc.
ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**

Page 18 Of 24






View Report



Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini



CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

| PH | 7.5 | 4.5 - 7.5 |
|--------------------|------------------|---------------|
| SPECIFIC GRAVITY | 1.015 | 1.005 - 1.030 |
| PROTEIN | NOT DETECTED | NEGATIVE |
| GLUCOSE | NOT DETECTED | NEGATIVE |
| KETONES | NOT DETECTED | NOT DETECTED |
| BLOOD | DETECTED (TRACE) | NOT DETECTED |
| BILIRUBIN | NOT DETECTED | NOT DETECTED |
| UROBILINOGEN | NORMAL | NORMAL |
| NITRITE | NOT DETECTED | NOT DETECTED |
| LEUKOCYTE ESTERASE | NOT DETECTED | NOT DETECTED |

MICROSCOPIC EXAMINATION, URINE

| RED BLOOD CELLS | 2 - 3 | NOT DETECTED | /HPF |
|------------------|-------|--------------|------|
| PUS CELL (WBC'S) | 1-2 | 0-5 | /HPF |
| EPITHELIAL CELLS | 5-7 | 0-5 | /HPF |

NOT DETECTED **CASTS** NOT DETECTED **CRYSTALS**

BACTERIA NOT DETECTED NOT DETECTED YEAST **NOT DETECTED** NOT DETECTED

NOTE:- MICROSCOPIC EXAMINATION OF URINE IS PERFORMED BY **REMARKS**

CENTRIFUGE

URINARY SEDIMENT.

Dr. Kamlesh I Prajapati **Consultant Pathologist**





Page 19 Of 24

View Report

PERFORMED AT:







CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 04/01/2024 08:57:22

DELHI REPORTED :05/01/2024 14:22:13 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u> Results **Biological Reference Interval** Units

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

| Presence of | Conditions | | | |
|--|---|--|--|--|
| Proteins | Inflammation or immune illnesses | | | |
| Pus (White Blood Cells) | Urinary tract infection, urinary tract or kidney stone, tumors or any kind | | | |
| | of kidney impairment | | | |
| Glucose | Diabetes or kidney disease | | | |
| Ketones | Diabetic ketoacidosis (DKA), starvation or thirst | | | |
| Urobilinogen | Liver disease such as hepatitis or cirrhosis | | | |
| Blood | Renal or genital disorders/trauma | | | |
| Bilirubin | Liver disease | | | |
| Erythrocytes | Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary | | | |
| | tract infection and glomerular diseases | | | |
| Leukocytes | Urinary tract infection, glomerulonephritis, interstitial nephritis either | | | |
| | acute or chronic, polycystic kidney disease, urolithiasis, contamination by | | | |
| | genital secretions | | | |
| Epithelial cells | Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or | | | |
| | bladder catheters for prolonged periods of time | | | |
| | | | | |
| Granular Casts | Low intratubular pH, high urine osmolality and sodium concentration, | | | |
| | interaction with Bence-Jones protein | | | |
| Hyaline casts | Physical stress, fever, dehydration, acute congestive heart failure, renal | | | |
| | diseases | | | |
| Calcium oxalate | Metabolic stone disease, primary or secondary hyperoxaluria, intravenous | | | |
| | infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl | | | |
| | oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of | | | |
| *** | ethylene glycol or of star fruit (Averrhoa carambola) or its juice | | | |
| Uric acid | arthritis | | | |
| Bacteria | Urinary infectionwhen present in significant numbers & with pus cells. | | | |
| Trichomonas vaginalis Vaginitis, cervicitis or salpingitis | | | | |

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 20 Of 24

View Report



Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini







PATIENT NAME: UNIKA SACHDEVA

CODE/NAME & ADDRESS: C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 REF. DOCTOR : SELF

ACCESSION NO: 0062XA000193

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID: ABHA NO : AGE/SEX :41 Years

DRAWN :

RECEIVED : 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED

K. I. Prejspati

Dr. Kamlesh I Prajapati Consultant Pathologist



Page 21 Of 24

View Details

View Report



Agilus Diagnostics Ltd. Plot No.160,Pocket D-11 Sector 8, Rohini





REF. DOCTOR: SELF PATIENT NAME: UNIKA SACHDEVA

CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID:

DRAWN

RECEIVED: 04/01/2024 08:57:22

REPORTED :05/01/2024 14:22:13

Test Report Status Results Biological Reference Interval Units <u>Final</u>

ABHA NO

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

| THYROID PANEL, SERUM | | | |
|----------------------|--------|---|-------|
| Т3 | 109.10 | Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0 |) |
| T4 | 9.06 | Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70 | μg/dL |
| TSH (ULTRASENSITIVE) | 0.564 | Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Associatio 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000 | • |

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Total T4 FT4 Total T3 **Possible Conditions** Sr. No. TSH

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**



Page 22 Of 24

View Report

PERFORMED AT:



8800465156



PATIENT NAME: UNIKA SACHDEVA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : UNIKF17108262 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 04/01/2024 08:57:22 DELHI ABHA NO REPORTED :05/01/2024 14:22:13 **NEW DELHI 110030**

Test Report Status Final Results Biological Reference Interval Units

| 1 | High | Low | Low | Low | (1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) | |
|---|------------|--------|--------|--------|--|--|
| | | | | | Post Thyroidectomy (4) Post Radio-Iodine treatment | |
| 2 | High | Normal | Normal | Normal | (1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid | |
| | | | | | hormone replacement therapy (3) In cases of Autoimmune/Hashimoto | |
| | | | | | thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical | |
| | | | | | inflammation, drugs like amphetamines, Iodine containing drug and | |
| | | | | | dopamine antagonist e.g. domperidone and other physiological reasons. | |
| 3 | Normal/Low | Low | Low | Low | (1) Secondary and Tertiary Hypothyroidism | |
| 4 | Low | High | High | High | (1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre | |
| | | | | | (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid | |
| | | | | | hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 | |
| | | | | | replacement therapy (7) First trimester of Pregnancy | |
| 5 | Low | Normal | Normal | Normal | (1) Subclinical Hyperthyroidism | |
| 6 | High | High | High | High | (1) TSH secreting pituitary adenoma (2) TRH secreting tumor | |
| 7 | Low | Low | Low | Low | (1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent | |
| | | | | | treatment for Hyperthyroidism | |
| 8 | Normal/Low | Normal | Normal | High | (1) T3 thyrotoxicosis (2) Non-Thyroidal illness | |
| 9 | Low | High | High | Normal | (1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies | |

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

K.I. Prejspati

Dr. Kamlesh I Prajapati Consultant Pathologist





Page 23 Of 24

View Details

View Report

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No.160,Pocket D-11 Sector 8, Rohini

Patient Ref. No. 775000005972050



REF. DOCTOR: SELF **PATIENT NAME: UNIKA SACHDEVA**

CODE/NAME & ADDRESS: C000138376 ACCESSION NO: 0062XA000193 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030 8800465156

PATIENT ID : UNIKF17108262

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 04/01/2024 08:57:22 REPORTED :05/01/2024 14:22:13

Test Report Status Results Biological Reference Interval **Final** Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

K. I. Prejapati

Dr. Kamlesh I Prajapati **Consultant Pathologist**

Page 24 Of 24





View Report

PERFORMED AT:

Agilus Diagnostics Ltd. Plot No.160, Pocket D-11 Sector 8, Rohini